48 active trials 32 recruiting 26 disease areas 7 changes in 30 days
| Early Phase 1 | 1 | |
| Phase 1 | 10 | |
| Phase 1/2 | 2 | |
| Phase 2 | 16 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 2 | ||||
| NCT06377540 | MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin Lymphoma | Autologous Stem Cell Transplant | Recruiting | 2026-09-29 |
| NCT04105270 | RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A… | Adenocarcinoma of Lung | Recruiting | 2026-09-17 |
| NCT06792825 | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and… | Follicular Lymphoma | Recruiting | 2026-08-12 |
| NCT05805605 | Allo HSCT Using RIC and PTCy for Hematological Diseases | Acute Myelogenous Leukemia | Recruiting | 2026-07-06 |
| NCT03314974 | Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders | Acute Leukemia | Recruiting | 2026-06-25 |
| NCT06872333 | Allo HSCT for High Risk Hemoglobinopathies | Graft Failure | Recruiting | 2026-06-04 |
| NCT06412497 | MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and… | Severe Aplastic Anemia | Recruiting | 2026-06-03 |
| NCT07493538 | MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity… | AML | Recruiting | 2026-04-16 |
| NCT05735717 | MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies | Hematologic Malignancy | Recruiting | 2026-04-06 |
| NCT06411795 | Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for… | Duodenal Neoplasm | Recruiting | 2026-02-03 |
| NCT03579875 | Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders | Fanconi Anemia | Recruiting | 2026-01-30 |
| NCT03125642 | Auto Stem Cell Transplant for Lymphoma Patients | Non-Hodgkin Lymphoma | Recruiting | 2025-11-04 |
| NCT02605421 | Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients… | Neuroblastoma | Recruiting | 2025-10-21 |
| NCT03642626 | MT2017-45: CAR-T Cell Therapy for Heme Malignancies | Acute Lymphoblastic Leukemia | Active, Not Recruiting | 2026-01-23 |
| NCT02171104 | MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis | Mucopolysaccharidosis Disorders | Active, Not Recruiting | 2026-01-07 |
| NCT03674411 | Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy | Acute Myeloid Leukemia | Active, Not Recruiting | 2026-01-06 |
| Phase 1/2 | ||||
| NCT07008638 | Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the… | Acute Myeloid Leukemia | Recruiting | 2026-07-22 |
| NCT07591649 | Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT | Relapsed Adult AML | Recruiting | 2026-05-19 |
| Phase 1 | ||||
| NCT06594445 | HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML | Myeloid Malignancy | Recruiting | 2026-07-14 |
| NCT07560865 | First-in Cancer-Type Phase I Study of FT536 for Recurrent WHO Grade 4 Astrocytoma | Astrocytoma | Recruiting | 2026-05-01 |
| NCT07541573 | GTB-5550 in Advanced Solid Tumors | Tri-specific Killer Engager | Recruiting | 2026-04-23 |
| NCT06692426 | Trial of Cell Based Therapy for DMD | Duchenne Muscular Dystrophy | Recruiting | 2026-03-04 |
| NCT06693986 | Adenovirus (RGDCRAdCOX2F) | Adenocarcinoma of Pancreas | Recruiting | 2026-01-07 |
| NCT05338658 | Study of PAT in Patients With Solid Tumor Cancers | Metastasis | Recruiting | 2025-12-09 |
| NCT05363267 | NF-1, Nutraceutical Intervention | Neurofibromatosis 1 | Active, Not Recruiting | 2026-09-23 |
Leukemia (10) · Acute Myeloid Leukemia (AML) (8) · Myelodysplastic Syndromes (MDS) (7) · Acute Lymphoblastic Leukemia (ALL) (6) · Non-Hodgkin Lymphoma (6) · Chronic Myeloid Leukemia (CML) (3) · Follicular Lymphoma (3) · Hodgkin Lymphoma (3) · Ovarian Cancer (3) · Chronic Lymphocytic Leukemia (CLL) (2)